Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, P. R. China.
BMC Gastroenterol. 2024 Sep 6;24(1):302. doi: 10.1186/s12876-024-03397-3.
To evaluate and compare the efficacy and safety of Endoscopic Nasobiliary Drainage (ENBD) and Percutaneous Transhepatic Cholangiography Drainage (PTCD) in patients with advanced Hilar Cholangiocarcinoma (HCCA) through a meta-analysis of clinical studies.
We searched Chinese and English databases, including China National Knowledge Infrastructure (CNKI), Wanfang database, PubMed, Embase, Scopus, and Web of Science, for relevant literatures on PTCD and ENBD for advanced HCCA clinical trials. Two investigators independently screened the literatures, and the quality of the included studies was evaluated using the Newcastle-Ottawa Scale (NOS). The primary endpoint was the success rate of biliary drainage operation, while secondary endpoints included Total Bilirubin (TBIL) change, acute pancreatitis, biliary tract infection, hemobilia, and other complications. R software was used for data analysis.
A comprehensive database search, based on predefined inclusion and exclusion criteria, yielded 26 articles for this study. Analysis revealed that PTCD had a significantly higher success rate than ENBD [OR (95% CI) = 2.63 (1.98, 3.49), Z=6.70, P<0.05]. PTCD was also more effective in reducing TBIL levels post-drainage [SMD (95%CI) =-0.13 (-0.23, -0.03), Z=-2.61, P<0.05]. While ENBD demonstrated a lower overall complication rate [OR (95%CI) = 0.60 (0.43, 0.84), Z=-2.99, P<0.05], it was associated with a significantly lower incidence of post-drainage biliary hemorrhage compared to PTCD [OR=3.02, 95%CI: (1.94-4.71), Z= 4.89, P<0.01].
This meta-analysis compares the efficacy and safety of ENBD and PTCD for palliative treatment of advanced HCCA. While both are effective, PTCD showed superiority in achieving successful drainage, reducing TBIL, and lowering the incidence of acute pancreatitis and biliary infections. However, ENBD had a lower risk of post-drainage bleeding. Clinicians should weigh these risks and benefits when choosing between ENBD and PTCD for individual patients. Further research is needed to confirm these findings and explore long-term outcomes.
通过对内镜鼻胆管引流术(ENBD)和经皮经肝胆管引流术(PTCD)治疗晚期肝门部胆管癌(HCCA)的临床研究进行荟萃分析,评估和比较这两种方法的疗效和安全性。
我们检索了中文和英文数据库,包括中国知网(CNKI)、万方数据库、PubMed、Embase、Scopus 和 Web of Science,以获取有关晚期 HCCA 临床试验中 PTCD 和 ENBD 的相关文献。两名研究者独立筛选文献,并使用纽卡斯尔-渥太华量表(NOS)评估纳入研究的质量。主要终点是胆道引流手术的成功率,次要终点包括总胆红素(TBIL)变化、急性胰腺炎、胆道感染、血胆、和其他并发症。使用 R 软件进行数据分析。
根据预先设定的纳入和排除标准,对综合数据库进行搜索,共获得 26 篇研究文章。分析表明,PTCD 的成功率明显高于 ENBD[比值比(95%置信区间)=2.63(1.98, 3.49),Z=6.70,P<0.05]。PTCD 还更有效地降低引流后 TBIL 水平[标准化均数差(95%置信区间)=-0.13(-0.23, -0.03),Z=-2.61,P<0.05]。虽然 ENBD 的总体并发症发生率较低[比值比(95%置信区间)=0.60(0.43, 0.84),Z=-2.99,P<0.05],但与 PTCD 相比,引流后胆血的发生率明显较低[比值比=3.02,95%置信区间:(1.94-4.71),Z=4.89,P<0.01]。
本荟萃分析比较了 ENBD 和 PTCD 治疗晚期 HCCA 的疗效和安全性。虽然两者都有效,但 PTCD 在实现成功引流、降低 TBIL 和降低急性胰腺炎和胆道感染的发生率方面表现出优势。然而,ENBD 引流后出血的风险较低。临床医生应在为个体患者选择 ENBD 和 PTCD 时权衡这些风险和益处。需要进一步的研究来证实这些发现并探讨长期结果。